What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 6 months ago
Can we stop RA before it happens?
Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent RA occurring in at-risk individuals.
https://t.co/vU4tRr7UJh https://t.co/cikU9pwaiT
CDC is tracking multiple reported U.S. monkeypox cases, and monitoring cases in persons in countries without endemic monkeypox and with no known travel links to an endemic area; current epidemiology suggests person-to-person community spread.
Dr. John Cush RheumNow
3 years 6 months ago
Price of a newly launched drug increased from $2115 per year in 2008 to $180 007 per year in 2021. In 2008 only 9% of drug cost >$150k/yr; this rose to 47% by 2021. Greater increases seen w/ biologics, rare disease and nononcology drugs https://t.co/JaGzNqCxdF
Dr. John Cush RheumNow
3 years 6 months ago
Gout Undertreatment Persists
Despite updated gout management guidelines from EULAR and BSR, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.
https://t.co/qW7ZaXbnx3 https://t.co/ZBKIjuQp10
Dr. John Cush RheumNow
3 years 6 months ago
Watch: RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
https://t.co/Lp25lP6ZZY https://t.co/wd5GCbaCLR
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media…
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
Dr. John Cush RheumNow
3 years 6 months ago
Video: Residual Pain in RA
Dr. Maxime Dougados discusses OP0052 at #EULAR2022.
https://t.co/gu1Svegss8 https://t.co/G1rRizG9gW
A nemesis is so much more than the "enemy". Your nemesis defines what matters most to you and how you will overcome. Seth Godin once said, “Pick your enemies, pick your future”.
Dr. John Cush RheumNow
3 years 6 months ago
Review on reactive arthritis & COVID: 22 articles , 25 pts (14M:11F), age 45 yrs. Oligoarthritis was most common. Onset (COVID to arthritis) was 6-48 days. Steroids in 13, 2 w/ SSZ, Sxs improved 22/25, mean resolution was 16 +/- 57 days https://t.co/0YABcjz9Gk https://t.co/W5Vnn1NjkD
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported significantly more SRI-4 response rates in DEUC vs PBO. PBO: 34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety. Will proceed to Phase 3 @RheumNow https://t.co/cZLv6bbHer
Dr. John Cush RheumNow
3 years 6 months ago
Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc w/ DMARD use in 82%; but was only 31% if not under Rheum care. Worse rheum retention with age >81, male, lower SES, older Rheums https://t.co/xUxWaksgsE
Poster Hall